DEC 04, 2014 12:00 AM PST

Researchers Use Evolutionary Tenets to Model Cancer Mutations: Spot potential therapeutic targets

WRITTEN BY: Judy O'Rourke
Cancer researchers aiming to gain new insights into the disease are looking at it from a new angle. Through the prism of evolutionary principles and computational modeling they are probing the role of particular genetic mutations in the Darwinian struggle among tumor and normal cells during cancer growth.

Healthy cells become malignant by amassing genetic mutations that lead to increased survival and reproduction. In contrast to prior research that regards cancer progression as the product of the unlimited build-up of these genetic mutations, researchers at the Moffitt Cancer Center, Tampa, Fla, are modeling cancer progression on the theory that cancer cells live in an environment that has finite resources (eg, space and nutrients) and is governed by evolutionary laws, which include a middle ground between multiplying and merely surviving.

The animal kingdom offers examples of either/or modes for longevity: aim for either a long lifespan or many babies. Elephants have few progeny and comparatively long lives, while rabbits have short lifespans and many babies. In their own way, cells that evolve to form cancers accomplish this by extending longevity or multiplying the number of offspring.

As with the big and small critters, cancer cell mutations can only travel down one evolutionary path at a time. So these cells can devote available resources in beefing up their defenses against attacks by normal tissue or tolerate a high mortality rate and prevail with extremely rapid proliferation-either/or.

Through computer simulations built on these concepts, the researchers determined that the frequency with which any genetic mutation is observed depends on its ability to increase the cell's fitness, its ability to survive, and reproduce-a process the researchers call "evolutionary triage."

"Genes that increase fitness are observed more frequently than those that do not," says Robert A. Gatenby, MD, chair of the Department of Diagnostic Imaging and co-director of the Cancer Biology and Evolution Program at Moffitt. "However, the effect of any mutation on cell fitness can change drastically depending on environmental factors such as blood flow, past genetic mutations, and the properties of competing cells. Currently, cancer biologists divide mutations into ‘drivers,' which promote tumor growth and ‘passengers,' which have no effect on growth. In the computer simulations, it was clear that many mutations could be drivers in one environment, but passengers in another."

Since driver mutations are common targets for cancer therapy, the scientists also simulated therapies that seek to disable driver genes. The researchers found that targeted therapies can destroy the mutated cells and shrink the tumor size, akin to results seen in clinical settings. But the range of tumor environments creates many mutational pathways to formation of a malignant cell. Cancer cells without the driver mutation that are resistant to therapy were almost always present and caused the tumor to reappear.

The researchers were surprised to find that some genes were never observed to be mutated in cancers. Mutations in these genes always scaled down the tumor cell's ability to survive or reproduce. When they did occur, evolutionary triage obliterated them due to survival of the fittest. "Our computer simulations demonstrate an unexpected result - genes that are never observed to be mutated might actually be the best targets for therapy. This is because up or down regulation of these genes unconditionally reduces cell fitness," Gatenby says.

With assistance from a bioinformatics expert from the Scripps Research Institute, La Jolla, Calif, 1,100 genes that are never mutated in human cancers were identified. The research group is now working to investigate the possibility of targeting "never" genes for therapy.
About the Author
  • Judy O'Rourke worked as a newspaper reporter before becoming chief editor of Clinical Lab Products magazine. As a freelance writer today, she is interested in finding the story behind the latest developments in medicine and science, and in learning what lies ahead.
You May Also Like
JUN 20, 2018
Cancer
JUN 20, 2018
Peruvian Plant's Unique Anti-Tumor Biological Mechanism Discovered
Plagiochiline A is a molecule that exhibits antiproliferative properties and is cytotoxic. New research outlines the unique biological mechanism valued as possible cancer therapy target....
JUN 25, 2018
Cancer
JUN 25, 2018
B-cell Lymphoma Develops After MPN JAK1/2 Therapy
Patients with myeloproliferative neoplasms treated with JAK1/2 inhibitor therapy are at increased risk of developing aggressive B-cell lymphoma due to pre-existing B-cell clone specifically a...
JUL 09, 2018
Cell & Molecular Biology
JUL 09, 2018
Scientists Found a New Way to Treat Lung Cancer
Small cell lung cancer is an aggressive type that can be fatal; there were few treatments for the disease. That may have changed....
JUL 10, 2018
Cancer
JUL 10, 2018
The ALFRED Analysis for Cancer Predisposition Genes
New proposed statistical method called ALFRED used to identify cancer predisposition genes....
AUG 07, 2018
Cancer
AUG 07, 2018
Potential Bcl-2 Targeted Therapy for Relapsed Multiple Myeloma Patients
Targeted therapy for Bcl-2 may be helpful in more than the two lymphoma diagnoses that were recently approved by the FDA....
OCT 08, 2018
Immunology
OCT 08, 2018
Natural Killer Cells to Aid in Cancer Therapy
Researchers utilize nanoparticles to stimulate NK cells that induce tumor cells to express PDL1, a protein involved in immune response messaging...
Loading Comments...